香港聯合交易所有限公司與證券及期貨事務監察委員會對本申請版本的內容概不負責，對其準確性或完整 性亦不發表任何聲明，並明確表示概不就因本申請版本全部或任何部分內容而產生或因倚賴該等內容而引 致的任何損失承擔任何責任。 四川百利天恒藥業股份有限公司 （「本公司」） （於中華人民共和國註冊成立的股份有限公司） 的申請版本 警告 本申請版本乃根據香港聯合交易所有限公司（「聯交所」）及證券及期貨事務監察委員會（「證監 會」）的要求而刊發，僅用作提供資訊予香港公眾人士。 本申請版本為草擬本，其內所載資料並不完整，亦可能會作出重大變動。您閱覽本文件，即代 表您知悉、接納並向本公司、其聯席保薦人、整體協調人、顧問或包銷團成員表示同意： 倘於適當時候向香港公眾人士提出要約或邀請，準投資者務請僅依據呈交香港公司註冊處處長 註冊的本公司招股章程作出投資決定；有關文本將於發售期內向公眾刊發。 (a) 本文件僅為向香港公眾人士提供有關本公司的資料，概無任何其他目的。投資者不應根 據本文件中的資料作出任何投資決定； (b) 在聯交所網站登載本文件或其補充、修訂或更換附頁，並不引起本公司、其聯席保薦 人、整體協調人、顧問或包銷團成員須在香 ...

Core Insights - The A-share market is stabilizing, leading to a resurgence in the private placement market, attracting top fund managers to participate in various projects [2][6] - Notable private placement projects have shown significant profitability, with over 90% of placements yielding floating profits for participating institutions [2][6] - The private placement market is becoming an important tool for public institutions to optimize their portfolios and seize structural opportunities [2][6] Fund Participation - On September 27, Baili Tianheng announced a private placement of 11.87 million shares at a price of 317 yuan per share, raising 3.764 billion yuan for innovative drug research [3][4] - The placement attracted 30 bidders, with 18 institutions, including 11 public fund companies, successfully participating [4] - Notable fund managers, such as Ge Lan and Zhao Bei, participated in the placements, indicating strong market interest [4][5] Market Performance - Following the private placements, both Baili Tianheng and Aishun's stock prices increased significantly, resulting in substantial floating profits for participating funds [5][6] - Baili Tianheng's stock rose by 17.63% from the placement price, while Aishun's stock increased by 28.6%, with major funds reporting profits exceeding 1 billion yuan [5][6] Market Trends - The private placement market has shown a "quantity and quality" increase this year, with 28 fund companies participating in 218 funds, raising a total of 5.864 billion yuan, a 70% increase from last year [6][7] - The performance of related stocks has also improved, with many stocks experiencing significant price increases post-placement, contributing to the profitability of funds [6][7] Investment Strategy - Fund managers express intentions to continue leveraging private placements to capture quality stock opportunities, emphasizing the importance of professional judgment in investment decisions [2][8] - The core logic for institutional investors in participating in private placements is the combination of existing stock and discount opportunities, allowing for large-scale accumulation without market impact [8]

Core Viewpoint - The A-share market is stabilizing, leading to a resurgence in the private placement market, with notable fund managers actively participating in recent projects, indicating a strong profit potential from these investments [3][9]. Group 1: Market Activity - As of September 28, 2023, 28 fund companies have participated in 218 private placement projects this year, with a total investment amounting to 5.864 billion yuan, surpassing the total for the entire previous year [9]. - Over 90% of the private placements have shown varying degrees of unrealized gains, reflecting a significant profit effect in the current market environment [3][9]. Group 2: Notable Projects - Baili Tianheng's recent private placement raised 3.764 billion yuan by issuing 11.8738 million shares at 317 yuan each, aimed at funding innovative drug research [5]. - The private placement of Aiyu Co. raised 3.5 billion yuan by issuing 291 million shares at 12.03 yuan each, with participation from 19 institutions, including major fund managers [6][7]. Group 3: Fund Manager Participation - Prominent fund managers such as Ge Lan, Zhao Bei, and Zhu Shao Xing have been actively involved in these private placements, with significant allocations from their respective funds [5][6]. - For instance, Zhongou Fund's allocation in Baili Tianheng amounted to 678 million yuan, while E Fund and other major firms also secured substantial shares [5][6]. Group 4: Performance and Returns - Following the private placements, both Baili Tianheng and Aiyu Co. saw their stock prices increase significantly, with Baili Tianheng's price rising by 17.63% and Aiyu Co. by 28.6% [6][7]. - The performance of stocks like Chip Origin and Dize Pharmaceutical has also been notable, with substantial unrealized gains reported by various funds involved in these placements [9][10]. Group 5: Investment Strategy Insights - Fund managers emphasize the importance of a long-term asset allocation strategy and professional judgment when participating in private placements, cautioning ordinary investors against blindly following trends [3][11]. - The private placement mechanism provides institutional investors with opportunities to build positions without market impact, which is crucial for large funds facing liquidity constraints [11].

Core Viewpoint - The capital market is increasingly focusing on the innovative drug sector, as evidenced by Bailitianheng's recent completion of a 3.764 billion yuan A-share private placement, attracting significant investment from top public funds, indicating strong institutional confidence in biotech companies with genuine innovation capabilities and overseas potential [2][3]. Group 1: Investment Details - Bailitianheng's private placement was priced at 317 yuan per share, issuing a total of 11.87 million shares to 18 specific investors, with public funds being the largest buyers [3]. - Notable investors include China Europe Fund, which subscribed for 678.82 million yuan, followed by other major funds like E Fund and GF Securities, with all top 10 subscription amounts exceeding 100 million yuan [4]. Group 2: Fund Manager Actions - Fund managers displayed a "reduce then increase" strategy, with China Europe Fund reducing its holdings before participating in the private placement, indicating a reassessment of the company's value [5]. - ICBC Credit Suisse Fund and Fortune Fund also participated significantly, with multiple products from these funds collectively investing over 5.62 billion yuan in Bailitianheng [5]. Group 3: Financial Performance - Bailitianheng's financial performance shows a stark contrast to the institutional enthusiasm, with a reported revenue of only 171 million yuan for the first half of 2025, a 96.92% year-on-year decline, and a net loss of 1.118 billion yuan [6]. - The company's R&D expenses surged to 1.039 billion yuan, reflecting the high-cost nature of innovative drug development [6]. Group 4: Market Position and Product Pipeline - As of September 26, 2025, Bailitianheng's stock price increased by 94.49% year-to-date, with a market capitalization of 154 billion yuan, ranking fourth among A-share innovative drug companies [7]. - The market is optimistic about its core product, BL-B01D1, which has received multiple breakthrough therapy designations, enhancing its market potential [7]. Group 5: Analyst Ratings and Market Sentiment - Recent analyst reports maintain a positive outlook on Bailitianheng, with several institutions issuing "strong buy" ratings, reflecting confidence in its future prospects [8][9]. - The innovative drug sector is increasingly categorized into "focused" companies like Bailitianheng and "dual-driven" companies that leverage traditional business cash flows to support innovation [10]. Group 6: Strategic Insights - Top fund managers emphasize the importance of innovation and international expansion as key growth drivers in the industry, with a focus on areas like ADC drugs and GLP-1 weight loss medications [10].

Core Insights - The A-share market is stabilizing, leading to a resurgence in the private placement market, attracting top fund managers to participate in various projects [1][5] - Notable private placement projects have shown significant profitability, with over 90% of placements yielding floating profits for participating institutions [1][5] - The trend of increasing participation in private placements is evident, with 28 fund companies and 218 funds involved this year, raising a total of 5.864 billion yuan, a 70% increase from the previous year [5][6] Group 1: Fund Participation - Prominent fund managers such as Ge Lan, Zhao Bei, and Zhu Shao Xing have actively participated in private placements, indicating a strong interest from well-known institutions [1][2] - The private placement by Baili Tianheng raised 3.764 billion yuan by issuing 11.8738 million shares at 317 yuan each, with significant participation from major fund companies [1][2] - The private placement by Aiyu Co. raised 3.5 billion yuan by issuing 291 million shares at 12.03 yuan each, with 19 institutions participating, including major fund companies like E Fund and GF Securities [3][4] Group 2: Market Performance - Following the private placements, both Baili Tianheng and Aiyu Co. saw their stock prices increase significantly, resulting in substantial floating profits for participating funds [3][6] - Baili Tianheng's stock price rose by 17.63% from the placement price, while Aiyu Co.'s stock price increased by 28.6%, showcasing the effectiveness of these placements [3][6] - The overall performance of stocks involved in private placements has been strong, with many stocks experiencing significant price increases, contributing to the profitability of the funds involved [5][6] Group 3: Investment Strategy - Fund managers emphasize the importance of a strategic approach to private placements, focusing on long-term asset allocation and professional judgment [1][7] - The private placement mechanism provides a unique opportunity for institutional investors to build positions without market impact, which is crucial for large funds [6][7] - There is a caution against retail investors blindly following institutional strategies, as the dynamics of private placements differ significantly from typical market operations [7]

Core Insights - The article discusses the rise of Baili Tianheng, a Chengdu-based biopharmaceutical company, and its founder Zhu Yi, who has recently been labeled as "Sichuan's richest man" due to the company's soaring market value. Zhu Yi emphasizes that this title is merely "paper wealth" and expresses more pressure than honor [1]. Group 1: New Drug Development - Baili Tianheng's core product, iza-bren (BL-B01D1), is a first-in-class dual antibody ADC that has achieved a 100% objective response rate (ORR) in clinical trials for treating EGFR-mutant non-small cell lung cancer [2][6]. - The company has submitted a listing application to the Chinese National Medical Products Administration (NMPA) and expects approval around June 2026, with a later launch in the U.S. anticipated by 2029 [6][10]. - The drug has been in development for over 10 years, with the research starting in 2014, highlighting the long timeline required for original innovation in the pharmaceutical industry [6][10]. Group 2: Investment and Expansion Plans - Baili Tianheng plans to invest an additional 2 billion yuan (approximately 0.3 billion USD) in a new facility in Chengdu Medical City, which will include a large workshop, transformation center, and laboratory [8][10]. - The new facility is expected to support the nationwide and partial global supply of iza-bren, with projected annual sales exceeding 10 billion yuan (approximately 1.5 billion USD) once production reaches 70% capacity [10]. Group 3: Future Aspirations - Zhu Yi aims for Baili Tianheng to become a leading multinational corporation (MNC) in oncology treatment within five years, with global commercialization expected by 2029 [11]. - The company is focusing on maintaining global leadership in research and development, clinical development capabilities, and supply chain management as key indicators of becoming an entry-level MNC [11]. Group 4: Chengdu's Biopharmaceutical Environment - Chengdu is seen as an advantageous location for biopharmaceutical development due to its improving business environment and the stability of its research teams, which is crucial for successful drug development [15][17]. - Zhu Yi notes that Chengdu's ability to attract high-end talent has improved, and he suggests further enhancements in policies related to international schools and healthcare for expatriates to boost talent attraction [16].

Core Insights - The EGFR x HER3 dual antibody ADC iza-bren (BL-B01D1) developed by Bai Li Tianheng has received multiple significant approvals and recognitions in September 2023, indicating its potential as a breakthrough treatment in oncology [1][2][3] Group 1: Regulatory Approvals - On September 5, 2023, iza-bren was officially included in the priority review list by the National Medical Products Administration (NMPA) for treating recurrent or metastatic nasopharyngeal carcinoma patients who have failed at least two lines of chemotherapy [1] - On September 10, 2023, iza-bren was listed as a breakthrough therapy for treating platinum-resistant recurrent epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer [2] - On September 17, 2023, iza-bren was proposed for inclusion as a breakthrough therapy for locally advanced or metastatic urothelial carcinoma patients who have failed prior platinum-based chemotherapy and PD-1/PD-L1 inhibitors, marking its seventh breakthrough therapy designation in China [2] Group 2: Clinical Research Achievements - Two studies of iza-bren were selected for the official news release program of the 2025 World Lung Cancer Conference (WCLC), showcasing the highest-rated research outcomes [1] - The Phase II study of iza-bren combined with Osimertinib for treating advanced or metastatic EGFR-mutant non-small cell lung cancer reported an overall response rate (ORR) of 100%, marking it as the first treatment regimen globally to achieve such a result [1] - In October 2023, iza-bren's first registered Phase III clinical trial results will be presented at the European Society for Medical Oncology (ESMO) annual meeting, with the results included in the prestigious Late-breaking Abstract (LBA) session [3] Group 3: Collaborative Efforts - Tai Mei Medical Technology has provided various digital clinical research solutions for the series of studies related to iza-bren, supporting the advancement of Chinese innovative drugs on the global stage [3] - The independent efficacy evaluation of the Phase II study of iza-bren was efficiently conducted using AI and digital systems, demonstrating the capabilities of Tai Mei Medical Technology in supporting clinical research [3]

Core Viewpoint - The A-share private placement market is currently very active, attracting multiple fund companies and notable fund managers to participate [1] Group 1: Private Placement Activities - Aishuo Co., Ltd. announced the results of its private placement, with 22 participating institutions, including two foreign institutions and various public and private funds, raising a total of 3.5 billion yuan by issuing 291 million shares at a price of 12.03 yuan per share [3] - E Fund was the second-largest recipient in the private placement, receiving 361 million yuan, alongside five other public funds that also participated [3] - In a separate announcement, Jingshun Great Wall Fund disclosed that ten of its actively managed equity funds participated in the private placement, with the highest individual fund value approaching 60 million yuan [3] Group 2: Fund Participation Details - E Fund's announcement indicated that four of its funds participated in the private placement, including two mixed funds managed by emerging fund manager Jia Jian, as well as a solar theme ETF and a new energy theme ETF [4] - Baili Tianheng reported that 18 professional investment institutions participated in its private placement, with a total allocation of 11,873,817 shares, amounting to 3.764 billion yuan [4] - Among the participating institutions, China Europe Fund received the most shares, totaling 2,141,397 shares worth 679 million yuan, while E Fund received 1,510,031 shares valued at 479 million yuan [4][5] Group 3: Fund Manager Contributions - Industrial Bank of China Fund announced that seven of its funds participated in Baili Tianheng's private placement, with a total cost of 323 million yuan [5] - According to reports from Fortune Fund, 15 of its funds participated in Baili Tianheng's private placement, with a total cost of 259 million yuan, including the Fortune Tianhui Growth Fund managed by Zhu Shaoxing, which received 315,457 shares valued at nearly 100 million yuan [6]

Core Points - The company has completed the issuance of 11,873,817 new shares, which were registered and managed on September 25, 2025, and will be tradable on the Shanghai Stock Exchange after the lock-up period ends [1][14] - The issuance will not change the company's control and complies with the listing conditions of the Shanghai Stock Exchange [2][23] - The total amount raised from this issuance is approximately RMB 3.76 billion, with a net amount of approximately RMB 3.73 billion after deducting issuance costs [8][13] Issuance Overview - The issuance involved 11,873,817 shares at a price of RMB 317.00 per share, resulting in a total fundraising amount of RMB 3,763,999,989.00 [8][12] - The issuance process followed necessary internal decision-making procedures and received approval from the board and shareholders [3][4] - The shares were issued to specific investors and are subject to a six-month lock-up period [9][19] Regulatory Approval - The issuance received approval from the Shanghai Stock Exchange on July 11, 2025, and from the China Securities Regulatory Commission on August 7, 2025 [4][10] Financial Impact - The issuance will increase the company's total assets and net assets, leading to a decrease in the debt-to-asset ratio, thereby enhancing the company's financial strength and debt repayment capability [24] - The capital structure will be optimized, providing effective support for future development [24] Shareholder Structure - The issuance will not result in significant changes to the company's business structure or governance, and the controlling shareholder remains unchanged [25][26] - The issuance was conducted fairly and in compliance with relevant laws, ensuring that no major shareholders or related parties were involved in the subscription process [18][22] Underwriters and Legal Advisors - The main underwriter for this issuance is CITIC Securities Co., Ltd., with joint underwriters including Huatai United Securities and Goldman Sachs (China) Securities [10][11]

登录新浪财经APP 搜索【信披】查看更多考评等级 建信现金增利货币市场基金B类基金份额在中国建设银行销售渠道暂停大额申购、大额转换转入、定期 定额投资公告 公告送出日期：2025年9月27日 1. 公告基本信息 ■ 2.其他需要提示的事项 （1）建信现金增利货币市场基金B类基金份额将于2025年9月29日起在中国建设银行销售渠道暂停大额 申购、大额转换转入、定期定额投资业务，其他业务参照其他相应公告执行。 （3）投资者如有疑问，请拨打本基金管理人客户服务热线：400-81-95533 （免长途通话费），或登录 网站www.ccbfund.cn获取相关信息。 风险提示：本公司承诺以诚实信用、勤勉尽责的原则管理和运用基金财产，但不保证本基金一定盈利， 也不保证最低收益。基金的过往业绩不代表未来业绩。敬请广大投资者注意投资风险，理性投资。 特此公告。 建信基金管理有限责任公司 2025年9月27日 建信纳斯达克100指数型证券投资基金（QDII）基金暂停大额申购、定期定额投资公告 公告送出日期：2025年9月27日 1. 公告基本信息 ■ （2）建信现金增利货币市场基金B类基金份额在中国建设银行销售渠道暂停大额申购 ...